Dr. Tracey L. Evans, MD

Dr. Evans practices at Paoli Hospital in Paoli, Pennsylvania, part of Main Line Health System.

Dr. Evans' NPI, 1033152319, was assigned on June 14, 2006. Dr. Evans graduated from Perelman School of Medicine - Philadelphia in 1996. Dr. Evans holds Pennsylvania license MD419780.

Dr. Evans' primary practice is Paoli Hospital, at 255 West Lancaster Avenue, Paoli, PA 19301 in Chester County. The practice phone is (610) 648-1000.

Dr. Evans' primary practice is Paoli Hospital in Paoli, Pennsylvania, part of Main Line Health System. Dr. Evans is also affiliated with Lankenau Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Evans to 2 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Evans practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Evans' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Evans is board certified in hematology by the American Board of Internal Medicine. Dr. Evans is licensed in Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Evans treats.

CMS data shows 48,171 Medicare services from Dr. Evans across 27 procedure codes in 2024, for 516 Medicare patients. Medicare paid $864,080 for them.

CMS counts 516 Medicare patients who saw Dr. Evans in 2024. The largest group is 75 to 84, with 233 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Evans' median patient age at 66, with 55% women.

In 2024, Dr. Evans wrote 644 Medicare Part D claims for 140 patients. 70% of them were for generic drugs. CMS names the drug for 441 of them, across 15 drugs with 11 or more claims each, at $110,553 in total drug cost. In 2023, CMS named 644 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Evans for performance year 2024, reported through an alternative payment model (APM). Dr. Evans accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Evans as offering telehealth.

Dmand AI links 91 papers to Dr. Evans, published from 2010 to 2024. 2017 was the busiest year, with 13. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Evans has published most often in Clin Lung Cancer. Dr. Evans' most frequent co-authors are Corey J. Langer, MD, Charu Aggarwal, MD, MPH and Joshua Michael Bauml, MD.

Dmand AI links Dr. Evans to 1 clinical trial. Conditions studied include Adenocarcinoma of Lung and Adenocarcinoma.

CMS Open Payments shows 1,021 general payments to Dr. Evans from 61 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. AstraZeneca Pharmaceuticals LP paid the most, $318,096.

Dmand AI lists 2 awards for Dr. Evans, most recently Philadelphia Magazine in 2014.

Dr. Evans graduated from Perelman School of Medicine - Philadelphia in 1996.

Dr. Evans is in network with 22 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.